Loss of IL36RN function does not confer susceptibility to psoriasis vulgaris

Journal of Investigative Dermatology

Volumn 134, Issue 1, 2014, Pages 271-273

  Berki, Dorottya M ^a   Mahil, Satveer K ^a   David Burden, A ^b   Trembath, Richard C ^a,c   Smith, Catherine H ^a   Capon, Francesca ^a   Barker, Jonathan N ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; INTERLEUKIN 36 RECEPTOR ANTAGONIST; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG;

ACRODERMATITIS CONTINUA; ALLELE; AMINO ACID SUBSTITUTION; CELL INFILTRATION; DISEASE PREDISPOSITION; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; HUMAN; INFLAMMATORY CELL; LETTER; LOSS OF FUNCTION MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; PUSTULOSIS PALMOPLANTARIS; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84891035727     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.285     Document Type: Letter

References (12)

1. Adzhubei IA, Schmidt S, Peshkin L et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248-9
2. Blumberg H, Dinh H, Dean C Jr et al. (2010) IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J Immunol 185: 4354-62
3. Blumberg H, Dinh H, Trueblood ES et al. (2007) Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med 204: 2603-14
4. Carrier Y, Ma HL, Ramon HE et al. (2011) Interregulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol 131: 2428-37
5. Johnston A, Xing X, Guzman AM et al. (2011) IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol 186: 2613-22
6. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protocols 4: 1073-81
7. Marrakchi S, Guigue P, Renshaw BR et al. (2011) Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 365: 620-8
8. Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N et al. (2013) Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol 133: 1904-7
9. Onoufriadis A, Simpson MA, Pink AE et al. (2011) Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 89: 432-7
10. Setta-Kaffetzi N, Navarini AA, Patel VM et al. (2013) Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol 133: 1366-9
11. Strange A, Capon F, Spencer CC et al. (2010) A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 42: 985-90
12. Tortola L, Rosenwald E, Abel B et al. (2012) Psoriasiform dermatitis is driven by IL-36- mediated DC-keratinocyte crosstalk. J Clin Invest 122: 3965-76